Clinical application of 131I-HIPDM in the patients with chronic obstructive pulmonary disease

N,N,N'-trimethyl-N'-2 hydroxy-3-methyl-5-iodobenzyl-1,3-propanediamine iodine-131 (HIPDM) as a lung imaging and metabolic tracer in patients with chronic obstructive pulmonary disease (COPD) were used. 0.4 mCi 131I-HIPDM was rapidly injected into the antecubital vein. The imaging of 131I-HIPDM in the lung was different in various groups. 131I-HIPDM of the clearance by the lungs was a biphasic curve (rapid phase and slow phase). It was displayed that rapid phase of the clearance curve of 131I-HIPDM in the lungs in subjects with chronic obstructive pulmonary emphysema, especially those of smokers were very slow. The rapid phase of the 131I-HIPDM of the right lung clearance was significantly correlated with Forced Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), Functional Residual Capacity (FRC), Residual Volume (RV), Total Lung Capacity (TLC) p < 0.01; Peak Expiratory Flow Rate (PEFR), Vital Capacity (VC), Maximum Ventilatory Volume (MVV), Arterial oxygen tension (PaO2) p < 0.05. Smoking influence on clearance of 131I-HIPDM of the lung including normal smokers with normal lung function. It was considered that the analysis of the lung release of 131I-HIPDM forms a new lung dysfunction index and it was useful that found early lung damage.